✦ LIBER ✦

Four-Year Clinical Follow-Up After Implantation of the Endeavor Zotarolimus-Eluting Stent: ENDEAVOR I, the First-in-Human Study

✍ Scribed by Ian T. Meredith; John Ormiston; Robert Whitbourn; I. Patrick Kay; David Muller; Jeffrey J. Popma; Donald E. Cutlip; Peter J. Fitzgerald

Book ID: 113444353
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 93 KB
Volume: 100
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2007.08.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five-year clinical follow-up after impla

Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study

✍ Ian T. Meredith; John Ormiston; Robert Whitbourn; I. Patrick Kay; David Muller; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract Objective: To evaluate the 5‐year clinical outcomes of patients treated with the Endeavor zotarolimus‐eluting stent (ZES) in the ENDEAVOR I first‐in‐human study. Background: ENDEAVOR I was a prospective, nonrandomized, multicenter study of the Endeavor ZES in 100 consecutive patients wi

Endeavor I Four-Year Clinical Results: F

Endeavor I Four-Year Clinical Results: First-In-Human Safety and Efficacy Study of the Endeavor Zotarolimus-Eluting Stent

✍ I. Meredith; J. Ormiston; R. Whitbourn; I. Kay; D. Muller 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Extended follow-up safety and effectiven

Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: Two-year follow-up from the E-Five Registry

✍ Ian Meredith; Martin Rothman; Andrejs Erglis; Keyur Parikh; Chaim Lotan; for the 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 2 views

## Abstract Objectives: To present data from the cohort of patients in the all‐comers Endeavor zotarolimus‐eluting stent (ZES) registry (E‐Five) who underwent 2‐year follow‐up. Background: The Endeavor ZES has been shown to be safe and efficacious for treatment of single, de novo lesions in patient

The clinical evaluation of the Endeavor

The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study

✍ Shigeru Saito; Ross Prpic; Jeffery J. Popma; John Alexander; Mitchell W. Krucoff 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB